Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Example Group: ConceptualCohortDefinition: Meet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria

Generated Narrative: Group 279340

version: 4; Last updated: 2024-11-16 19:36:32+0000

Profile: ConceptualCohortDefinition

Artifact Author: Brian S. Alper:

Artifact related artifact: No display for RelatedArtifact (type: cite-as; citation: CohortDefinition: Meet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria [Database Entry: FHIR Group Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 279340. Revised 2024-09-29. Available at: https://fevir.net/resources/Group/279340. Computable resource at: https://fevir.net/resources/Group/279340.)

url: https://fevir.net/resources/Group/279340

identifier: FEvIR Object Identifier/https://fevir.net/FOI/279340

title: ConceptualCohortDefinition: Meet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria

status: Active

publisher: Computable Publishing LLC

contact: support@computablepublishing.com

description:

Meet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria a. T1DM-specific criteria ..i. Diagnosis of T1DM based on the World Health Organization (WHO) diagnostic criteria ..ii. have been on the following daily insulin therapy for at least 1 year ...1) multiple daily injection of long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) and rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine), or ...2) continuous subcutaneous insulin infusion (CSII) ..iii. are between 18 and 64 years old at the time of informed consent ..iv. have a body mass index of 18.5 to 30.0 kg/m2 at the time of screening b. T2DM-specific criteria ..i. Diagnosis of T2DM based on the World Health Organization (WHO) diagnostic criteria ..ii. have received the following daily insulin therapy with or without oral anti-hyperglycemic medications (OAMs) for at least 1 year ...1) insulin: long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) alone, or in combination with rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine) or CSII ...2) OAM: up to 3 of the following OAMs in accordance with local regulations: metformin, dipeptidyl peptidase-4 inhibitor, sodium glucose cotransporter 2 inhibitor, sulfonylurea (should not be more than half of maximum approved doses), glinides, alpha-glucosidase inhibitor, or thiazolidine ..iii. are between 20 and 70 years old at the time of informed consent ..iv. have a body mass index of 18.5 to 35.0 kg/m2 at the time of screening

copyright:

https://creativecommons.org/licenses/by-nc-sa/4.0/

membership: Conceptual

combinationMethod: Any of

characteristic

code: Defined by Reference

value: CohortDefinition: T1DM-specific criteria

exclude: false

description:

T1DM-specific criteria i. Diagnosis of T1DM based on the World Health Organization (WHO) diagnostic criteria ii. have been on the following daily insulin therapy for at least 1 year ..1) multiple daily injection of long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) and rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine), or...2) continuous subcutaneous insulin infusion (CSII) iii. are between 18 and 64 years old at the time of informed consent iv. have a body mass index of 18.5 to 30.0 kg/m2 at the time of screening

characteristic

code: Defined by Reference

value: CohortDefinition: T2DM-specific criteria

exclude: false

description:

T2DM-specific criteria i. Diagnosis of T2DM based on the World Health Organization (WHO) diagnostic criteria ii. have received the following daily insulin therapy with or without oral anti-hyperglycemic medications (OAMs) for at least 1 year ..1) insulin: long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) alone, or in combination with rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine) or CSII ..2) OAM: up to 3 of the following OAMs in accordance with local regulations: metformin, dipeptidyl peptidase-4 inhibitor, sodium glucose cotransporter 2 inhibitor, sulfonylurea (should not be more than half of maximum approved doses), glinides, alpha-glucosidase inhibitor, or thiazolidine iii. are between 20 and 70 years old at the time of informed consent iv. have a body mass index of 18.5 to 35.0 kg/m2 at the time of screening